AMSTERAM and IRVINE, California, June 1, 2011 /PRNewswire/ -- Agendia, a
commercial-stage molecular cancer diagnostics company, announced today that
it will present results from four completed and one ongoing study, at the
Annual Meeting of the American Society of Clinical Oncology (ASCO). Agendia
will publish the results of an additional study in conjunction with the
event. The meeting will be held from June 3-7, 2011 at McCormick Place in
Chicago, IL.
Currently on the market in the US and Europe, Agendia's Symphony(TM) suite of molecular diagnostic breast cancer tests enables physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers.
Agendia's lead product, Mammaprint(R), is currently the only molecular diagnostic breast cancer recurrence test available on the market to have received FDA clearance. Agendia's product development pipeline includes a further extension of its breast cancer tests as well as similar molecular diagnostic products for colon cancer.
All of the abstracts listed below can currently be found online at www.ASCO.org. Presentation details are as follows (all times are in Central Time).
Monday, June 6, 2011
Breast Cancer
1. Poster Presentation: Combined use of MammaPrint and Molecular Subtyping Profile (BluePrint(TM)) identifies subgroups with marked differences in response to neo-adjuvant treatment.
- Lead Author: F. de Snoo, P. Roepman, O. Krijgsman, R.A. Bender, R. Bernards, A. Glas
- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A
2. Poster Presentation: A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites.
- Lead Author: W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R.A. Bender, J. Carroll, R. Bernards
- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A
3. Poster Presentation: Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.
- Lead Author: G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, J.H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I.B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer, R. A. Bender
- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A
4. Publication-only Abstract: Comparison of MammaPrint and TargetPrint(R) with clinical parameters in patients with breast cancer: Findings from a prospective U.S. cohort.
- Lead Author: K. B. Deck, R. Sinha, D. Kerlin, J. Barone, E. Rivera, A. A. Garcia, K. Yao, L. Stork-Sloots, R. A. Bender, B. Nguyen
Colorectal Cancer
5. Poster Presentation: The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint(R).
- Lead Author: R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, K. van der Hoeven, B. Glimelius, F. Bibeau
- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A
6. Poster Presentation & Discussion: The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer.
- Lead Author: I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G. Capella
- Presentation Time: 8:00 AM - 12:00 PM; Discussion Time: 11:30 AM to 12:30 PM; Location: Hall D1
About Agendia
Agendia is an innovative molecular diagnostic company, striving to bring more effective, individualized treatments within reach of patients. Building on a genomics platform for tumour gene expression profiling, the company's tests help physicians more accurately select a course of cancer treatment for their patients. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology. Agendia is based in Amsterdam, the Netherlands and in Irvine, California. For more information, please visit http://www.agendia.com.
SOURCE Agendia B.V.
Advertisement
Currently on the market in the US and Europe, Agendia's Symphony(TM) suite of molecular diagnostic breast cancer tests enables physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers.
Advertisement
Agendia's lead product, Mammaprint(R), is currently the only molecular diagnostic breast cancer recurrence test available on the market to have received FDA clearance. Agendia's product development pipeline includes a further extension of its breast cancer tests as well as similar molecular diagnostic products for colon cancer.
All of the abstracts listed below can currently be found online at www.ASCO.org. Presentation details are as follows (all times are in Central Time).
Monday, June 6, 2011
Breast Cancer
1. Poster Presentation: Combined use of MammaPrint and Molecular Subtyping Profile (BluePrint(TM)) identifies subgroups with marked differences in response to neo-adjuvant treatment.
- Lead Author: F. de Snoo, P. Roepman, O. Krijgsman, R.A. Bender, R. Bernards, A. Glas
- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A
2. Poster Presentation: A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites.
- Lead Author: W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R.A. Bender, J. Carroll, R. Bernards
- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A
3. Poster Presentation: Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.
- Lead Author: G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, J.H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I.B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer, R. A. Bender
- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A
4. Publication-only Abstract: Comparison of MammaPrint and TargetPrint(R) with clinical parameters in patients with breast cancer: Findings from a prospective U.S. cohort.
- Lead Author: K. B. Deck, R. Sinha, D. Kerlin, J. Barone, E. Rivera, A. A. Garcia, K. Yao, L. Stork-Sloots, R. A. Bender, B. Nguyen
Colorectal Cancer
5. Poster Presentation: The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint(R).
- Lead Author: R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, K. van der Hoeven, B. Glimelius, F. Bibeau
- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A
6. Poster Presentation & Discussion: The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer.
- Lead Author: I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G. Capella
- Presentation Time: 8:00 AM - 12:00 PM; Discussion Time: 11:30 AM to 12:30 PM; Location: Hall D1
About Agendia
Agendia is an innovative molecular diagnostic company, striving to bring more effective, individualized treatments within reach of patients. Building on a genomics platform for tumour gene expression profiling, the company's tests help physicians more accurately select a course of cancer treatment for their patients. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology. Agendia is based in Amsterdam, the Netherlands and in Irvine, California. For more information, please visit http://www.agendia.com.
SOURCE Agendia B.V.
